PDS Biotech to Announce First Quarter 2024 Financial Results on May 15, 2024
PRINCETON, N.J., May 07, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage...
PRINCETON, N.J., May 07, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage...
SUMMIT, PEAK and APEX registration-directed clinical trial enrollment remains on track; topline results expected from all three studies in 2025...
Phase 1 data for CRB-701 (SYS6002) to be presented at ASCO Annual Meeting on June 1, 2024 $116M of capital...
BEDMINSTER, N.J., May 07, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused...
SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering,...
WNBA icon Sheryl Swoopes and New York elected officials will attend “MammoGlam” events in Harlem and the Bronx to promote...
Call Scheduled for Wednesday, May 15, 2024, at 9:00 a.m. ETDENVER--(BUSINESS WIRE)--TriSalus Life Sciences® Inc., (Nasdaq: TLSI), an oncology company...
New data finds AlphaVac F1885 System safe in patients with acute intermediate-risk pulmonary embolism (PE) and provides significant improvement in...
Transaction is part of wide-ranging collaboration to combine Quest's oncology expertise and scale with PathAI's AI and digital pathology innovations...
WOBURN, MA / ACCESSWIRE / May 6, 2024 / Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of...
DUBLIN--(BUSINESS WIRE)--The "U.S. Medical Kiosks Market - Focused Insights 2024-2029" report has been added to ResearchAndMarkets.com's offering. The U.S. Medical...
Diarrhea is one of the most common reasons for veterinary visits for dogs and the second most common reason for...
- Initial data demonstrates significant reduction in distant pancreatic cancer tumor growth rate starting from three weeks after first tumor...
OCALA, Fla., May 06, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the...
Conference Call and Webcast Scheduled for May 13, 2024 at 2:00 p.m. PT/5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., May...
- Stockholders’ equity significantly surpasses the $2.5 million minimum required by Nasdaq - Company is to seek Nasdaq’s formal confirmation...
HANOVER, Md., May 06, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical...
Final results demonstrate a significantly higher salvage treatment free survival rate (STFS) at 30 months of 89.6% in the...
Encouraging response rate shown; CR in 67% (6/9) of patients who completed the Induction Treatment Phase Padeliporfin VTP generally well-tolerated,...
ANGLE commissioned to develop a Parsortix-based Androgen Receptor detection assay for use in prostate cancer studies GUILDFORD, SURREY / ACCESSWIRE...